Prof Jorge Cortes speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He talks about the interim analysis from the OPTIC trial, a dose-ranging study of 3 starting doses of ponatinib for patients with chronic-phase chronic myeloid leukaemia (CP-CML).
Prof Cortes outlines the background and some detailed results from the study.
He highlights that this shows a trend toward dose-dependent efficacy and safety, and may provide a refined understanding of the ponatinib benefit/risk profile and its relation to dose.
Mature data from continued follow-up may support an alternate dosing regimen for patients with CP-CML.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.